DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: Floxuridine
Drug: Fluorouracil (5-FU)
Procedure: Conventional surgery
Procedure: Radiofrequency ablation

First Posted Date: 2004-03-15

Last Posted Date: 2018-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00004142

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: Doxorubicin Hydrochloride
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-03-15

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00004109

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Lung Cancer
Neurotoxicity
Ovarian Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Amifostine

First Posted Date: 2004-03-09

Last Posted Date: 2012-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00078845

Locations: 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 12 locations

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: Trastuzumab
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride

First Posted Date: 2004-02-27

Last Posted Date: 2018-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00016367

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-02-25

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 76

Registration Number: NCT00005991

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Phase 1

Completed

Conditions: Colorectal Cancer
Gallbladder Cancer
Pancreatic Cancer
Anal Cancer
Gastric Cancer

Interventions: Biological: Recombinant Interleukin-12

First Posted Date: 2004-02-19

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00003046

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Phase 1

Completed

Conditions: Liver Cancer

Interventions: Drug: TAC-101

First Posted Date: 2004-02-11

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00077142

Locations: 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Docetaxel
Drug: OSI-774
Drug: Cisplatin

First Posted Date: 2004-01-21

Last Posted Date: 2024-07-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00076310

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Natrecor in Pulmonary Hypertension

Phase 4

Terminated

Conditions: Pulmonary Hypertension
Lung Disease
Cancer
Cardiothoracic Surgery

Interventions: Drug: Nesiritide (Natrecor)
Procedure: Right Heart Catheterization

First Posted Date: 2004-01-06

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00075179

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Decitabine
Drug: Valproic acid

First Posted Date: 2003-12-31

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00075010

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy